

Claims:

1. A substituted cinnamamide compound, having the following structural formula:



M2.

2. An antidepressant and anxiolytic compound, having the following structural formula:



M2.

3. The compound according to claim 1 or 2, wherein the compound ~~can also be~~is present in a form of a solvate.

4. The compound according to claim 1 or 2, wherein the compound ~~can also be~~is present in a form of a pharmaceutically acceptable salt.


5. A pharmaceutical composition comprising the compound according to any one of claims 1-4.

6. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition ~~can be~~is in any doseable pharmaceutical form; optionally, the pharmaceutical form is selected from: tablets, capsules, oral liquids, oral lozenge, granules, pills, pulvises, pastes, pellets, suspensions, powders, solutions, injections, suppositories, soft ointments, hard ointments, creams, sprays, drops and patches; the tablets are optionally sugar-coated tablets, film-coated tablets or enteric-coated tablets; the capsules are optionally hard capsules or soft capsules; and the injections are optionally one of injection fluids, freeze-dried powder injections and liquid

drug injections.

7. The pharmaceutical composition according to claim 5, wherein when in use, the pharmaceutical composition ~~can be~~is used in combination with other antidepressant drugs or anxiolytic drugs, or the pharmaceutical composition further comprises another antidepressant drug or anxiolytic drug; the other antidepressant drug or anxiolytic drug being selected from: nefazodone, sulpiride, alprazolam, lorazepam, buspirone, tandospirone, methylphenidate, fluoxetine, paroxetine, sertraline, citalopram, lexapro, fluvoxamine, reboxetine, venlafaxine, flupenthixol, melitracen, and Neurostan.


8. A preparation method of the compound according to claim 1 or 2, wherein the preparation method being:



Intermediate A M2

reacting (E)-3-(3',4'-methylenedioxy-5'-trifluoromethyl-phenyl)-acrylic acid (i.e. intermediate A) with NH_3 to give compound M2.

9. The preparation method of the compound according to claim 8, comprising the following reaction route:



Intermediate A M2

10. The preparation method according to claim 9, comprising the following operation steps:

dissolving (E)-3-(3',4'-methylenedioxy-5'-trifluoromethyl-phenyl)-acrylic acid (i.e. intermediate A) in dichloromethane, adding a catalytic amount of N,N-dimethylformamide, dropping oxalyl chloride under ice bath, stirring at room temperature until the completion of reaction of raw materials; concentrating and drying the reaction liquid, then adding

dichloromethane to dissolve, dropping ammonia water under ice bath, reacting at room temperature until the completion of the reaction; and removing the solvent by evaporation under reduced pressure, then adding dilute hydrochloric acid to adjust it to be acidic, precipitating a solid, filtering and rinsing it with water to obtain a crude product, which is then subjected to silica gel column chromatography for purification to give M2.

11. Use of the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 in a medicine.

12. Use of the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 in the preparation of an antidepressant, anxiolytic, or antidepressant and anxiolytic drug.

13. Use of the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 in combination with another antidepressant drug or anxiolytic drug, or use of the compound according to any one of claims 1-4 in combination with one or more additional antidepressant drugs or anxiolytic drugs in the preparation of an antidepressant, anxiolytic, or antidepressants and anxiolytic drug; here, the other antidepressant drugs or anxiolytic drugs, or the additional antidepressant drugs or anxiolytic drugs ~~can be~~are selected from one or more of the following drugs for prevention and treatment of psychiatric disorders: e.g., nefazodone, sulpiride, alprazolam, lorazepam, buspirone, tandospirone, methylphenidate, fluoxetine, paroxetine, sertraline, citalopram, lexapro, fluvoxamine, reboxetine, venlafaxine, flupenthixol, melitracen, and Neurostan.

14. A method for preventing or treating psychiatric disorders, comprising administering the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 to a patient in need thereof.

15. The method according to claim 14, wherein the preventing or treating psychiatric disorders is anti-depression, anti-anxiety or anti-depression and anti-anxiety.